Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.

Catalent (CTLT) stock rises on reports of imminent $16.5 billion sale to Novo Holdings with FTC approval and EU Commission ...

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...

Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences ...

In February, Catalent agreed to be acquired by Novo Holdings for $63.50 a share. Novo Holdings will then sell three Catalent ...

Catalent (CTLT) and Novo Holdings announced that the European Commission has granted unconditional approval for the pending transaction under ...

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...

The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of Catalent (CTLT) by Novo ...